Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytek Biosciences, Inc. (Nasdaq: CTKB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer on the Nasdaq Global Select Market. These documents help investors and analysts understand Cytek’s financial condition, operating results and governance as a cell analysis solutions company focused on Full Spectrum Profiling™ (FSP®) flow cytometry instruments, reagents and services.
Cytek submits Form 10-Q quarterly reports and Form 10-K annual reports, which include details on revenue from products, services and reagents, gross margins, operating expenses such as research and development, sales and marketing, and general and administrative costs, as well as information on cash and marketable securities. These filings also discuss risk factors, market conditions and other elements relevant to its analytical laboratory instrument manufacturing business.
The company also files Form 8-K current reports to disclose material events. Recent 8-K filings have covered quarterly financial results under Item 2.02 (Results of Operations and Financial Condition) and outcomes of the annual meeting of stockholders under Item 5.07, including votes on director elections, executive compensation and ratification of the independent registered public accounting firm.
In addition, investors can review exhibits attached to these filings, such as press releases furnished as Exhibit 99.1, which provide narrative context for the numbers reported. Over time, the filings record Cytek’s progress in areas such as recurring revenue growth from services and reagents, expansion of its installed instrument base and capital allocation decisions.
On Stock Titan, Cytek’s SEC filings are updated in near real time from the EDGAR system. AI-powered summaries highlight key points from lengthy 10-K and 10-Q reports, and help users quickly identify information on revenue composition, operating trends and risk disclosures. The page also makes it easier to locate Form 4 and other insider-related filings when available, supporting research into trading activity and governance practices at CTKB.
Cytek Biosciences (CTKB) chief technology officer and director reported multiple equity transactions on November 18, 2025 related to previously granted restricted stock units (RSUs). Several RSU tranches were converted into common stock, including blocks of 1,981, 7,363, 5,525 and 6,162 shares, reflecting ongoing vesting of long-term equity awards. To cover tax withholding from these vestings, a total of 4,? (aggregate of 483, 1,793, 1,346 and 1,501) shares were withheld and surrendered to the company at a price of $5.53 per share, rather than being sold on the open market. After these transactions, the insider directly beneficially owned 6,073,327 shares of Cytek common stock. The RSU grants continue to vest over multiple years on specified quarterly and annual dates.
Cytek Biosciences (CTKB) senior executive reports RSU vesting and share withholding transactions. On November 18, 2025, the SVP, Global Sales and Services converted multiple batches of restricted stock units (RSUs) into common stock and had shares withheld to cover taxes.
Form 4 data shows RSU exercises adding 1,536, 2,210, and 3,625 shares of common stock, with tax withholding sales of 393, 565, and 927 shares at $5.53 per share. After these transactions, the executive directly owned 28,902 shares of Cytek common stock.
The filing also reports remaining unvested or unsettled RSUs, with derivative holdings of 8,714, 20,628, and 48,338 RSUs, each tied to multi-year vesting schedules that allocate specific fractions of each award to vest on set dates in May, August, November, and March until fully vested.
Cytek Biosciences, Inc. insider activity: the company’s Chief Legal Officer reported multiple transactions on common stock tied to vesting of restricted stock units (RSUs) on November 18, 2025. Several RSU awards were converted into common shares, each RSU representing a right to receive one share of Cytek common stock.
On the same date, shares were also withheld and surrendered to Cytek to cover tax withholding obligations at a price of $5.53 per share. After these RSU conversions and tax withholdings, the reporting person directly beneficially owned 115,641 shares of Cytek common stock. The RSU awards vest over four-year schedules with quarterly and annual vesting dates as described in the filing.
Cytek Biosciences, Inc. (CTKB) reported insider equity activity by its Chief Financial Officer on 11/18/2025. The filing shows the vesting and settlement of restricted stock units (RSUs) into common stock, along with shares withheld to cover taxes. The CFO acquired 6,320 shares of common stock upon RSU vesting, then had 2,032 shares withheld and surrendered to the company at $5.53 per share for tax obligations. A second RSU vesting added 13,051 shares, followed by 4,196 shares withheld at the same price for taxes. After these transactions, the CFO directly owned 80,714 shares of common stock and continued to hold additional unvested RSUs, reflecting ongoing equity-based compensation rather than an open-market sale.
Cytek Biosciences (CTKB) president and CEO, who also serves as a director, reported several equity transactions on November 18, 2025 related to restricted stock units (RSUs). Multiple RSU awards were converted into common stock, with 6,758, 11,781, 22,100 and 29,002 shares of common stock issued as each RSU grant vested.
To cover tax withholding from these vestings, the issuer withheld and received back 2,660, 4,636, 8,697 and 11,413 shares at a price of $5.53 per share. After the reported transactions, the executive beneficially owned 5,356,652 shares of Cytek common stock directly, and continued to hold RSU awards covering 4,514, 62,837, 206,273 and 386,699 units that will vest over multiple years on specified quarterly and annual dates.
Cytek Biosciences (CTKB) filed a Form 4 showing a director’s equity activity. On 11/18/2025, the reporting person acquired 2,181 shares of common stock through the vesting and settlement of restricted stock units, reported with transaction code "M." After this transaction, the person directly owned 12,359 shares of common stock.
The filing also shows activity in derivative securities. On the same date, 2,181 restricted stock units were converted into common stock at an exercise price of $0, leaving 13,819 restricted stock units beneficially owned directly. Each restricted stock unit represents a contingent right to receive one share of Cytek Biosciences common stock, subject to a multi-date vesting schedule.
Cytek Biosciences (CTKB)11/18/2025. The filing shows that 6,107 shares of common stock were acquired through the vesting and settlement of restricted stock units (RSUs), coded as transaction type “M,” which reflects the conversion of a derivative security into common stock.
After this transaction, the director beneficially owns 10,178 shares of Cytek common stock directly and continues to hold 63,111 RSUs. Each RSU represents the right to receive one share of common stock. The RSU award vests over time in tranches on specific dates, including portions vesting on August 18, November 18, March 10, May 18 and August 18 of future years until the award is fully vested.
Cytek Biosciences (CTKB) filed its Q3 2025 10‑Q, reporting total revenue of $52.3 million (product $38.1M; service $14.2M). Gross profit was $27.6 million and loss from operations was $9.2 million, resulting in a net loss of $5.5 million, or $0.04 per share.
Year‑to‑date revenue was $139.4 million with a net loss of $22.5 million. Cash and cash equivalents were $93.3 million, and marketable securities were $168.5 million. Deferred revenue was $28.7 million current and $16.3 million noncurrent, with remaining performance obligations totaling $45.1 million. Operating cash flow for the nine months was $(3.9) million. Shares outstanding were 127,864,830 as of September 30, 2025.
Cytek Biosciences, Inc. furnished a Current Report to announce that it issued a press release with financial results for the quarter ended September 30, 2025.
The press release is included as Exhibit 99.1 and was furnished under Item 2.02. The information furnished under Item 2.02 and the exhibit are not deemed filed under Section 18 of the Exchange Act. Cytek’s common stock trades on the Nasdaq Global Select Market under the symbol CTKB.
FAQ
What is the current stock price of Cytek Biosciences (CTKB)?
What is the market cap of Cytek Biosciences (CTKB)?
